UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

Journal of clinical oncology, 2007-06, Vol.25 (16), p.2218-2224

2007

Volltextzugriff (PDF)

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Clinical cancer research, 2021-05, Vol.27 (9), p.2435-2441

2021

Volltextzugriff (PDF)

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

Clinical cancer research, 2021-04, Vol.27 (7), p.1967-1973

2021

Volltextzugriff (PDF)

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma

Cancer, 2014-09, Vol.120 (17), p.2684-2693

2014

Volltextzugriff (PDF)

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)

European urology, 2023-09, Vol.84 (3), p.341-347

2023

Volltextzugriff (PDF)

Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma

The oncologist (Dayton, Ohio), 2022-06, Vol.27 (6), p.432-e452

2022

Volltextzugriff (PDF)

Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program

Cancer research (Chicago, Ill.), 2004-12, Vol.64 (24), p.9209-9216

2004

Volltextzugriff (PDF)

Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines

Journal of the National Comprehensive Cancer Network, 2012-09, Vol.10 (9), p.1081-1087

2012

Volltextzugriff (PDF)

Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer

Current opinion in oncology, 2013-05, Vol.25 (3), p.252-260

2013

Volltextzugriff (PDF)

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808

Clinical genitourinary cancer, 2023-10, Vol.21 (5), p.546-554

2023

Volltextzugriff (PDF)

Phase I/II Trial of Orteronel (TAK-700)―an Investigational 17,20-Lyase Inhibitor―in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical cancer research, 2014-03, Vol.20 (5), p.1335-1344

2014

Volltextzugriff (PDF)

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer

JAMA network open, 2024-10, Vol.7 (10), p.e2437871

2024

Volltextzugriff (PDF)

Predictors of response to targeted therapy in renal cell carcinoma

Archives of pathology & laboratory medicine (1976), 2012-05, Vol.136 (5), p.490-495

2012

Volltextzugriff (PDF)

Segregation of two spectrin isoforms: polarized membrane-binding sites direct polarized membrane skeleton assembly

Molecular biology of the cell, 1997-10, Vol.8 (10), p.1933-1942

1997

Volltextzugriff (PDF)

Using Intensity-Modulated Radiotherapy to Spare the Kidney in a Patient with Seminoma and a Solitary Kidney: A Case Report

Tumori, 2013-03, Vol.99 (2), p.38-42

2013

Volltextzugriff (PDF)

Prostate cancer, version 1.2014

Journal of the National Comprehensive Cancer Network, 2013-12, Vol.11 (12), p.1471-1479

2013

Volltextzugriff (PDF)

Chemotherapy for prostate cancer : implementing early systemic therapy to improve outcomes

Cancer chemotherapy and pharmacology, 2005-11, Vol.56 (S1), p.69-77

2005

Volltextzugriff (PDF)

Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5080-5080

2023

Volltextzugriff (PDF)

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.536-536

2022

Volltextzugriff (PDF)

Testicular cancer

Current opinion in oncology, 2004-05, Vol.16 (3), p.253-256

2004

Volltextzugriff (PDF)

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.4506-4506

2019

Volltextzugriff (PDF)

Correlation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.453-453

2018

Volltextzugriff (PDF)

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

Cancer research (Chicago, Ill.), 2004-12, Vol.64 (24), p.9209-9216

2004

Volltextzugriff (PDF)

Correlation of pathologic findings after brief neoadjuvant sorafenib (neoS) with results of dynamic-contrast enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) in patients (pts) with locally advanced or metastatic clear cell renal cell carcinoma (RCC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e15554-e15554

2013

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(36)
Buchkapitel
(2)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Life Sciences & Biomedicine
(19)
Science & Technology
(19)
Male
(16)
Oncology
(15)
Middle Aged
(9)
Aged
(8)
Aged, 80 And Over
(7)
Treatment Outcome
(7)
Tumors
(7)
Biological And Medical Sciences
(5)
Medical Sciences
(5)
Neoplasm Metastasis
(5)
Prostatic Neoplasms - Therapy
(5)
Urinary Bladder Neoplasms - Drug Therapy
(5)
Adult
(4)
Antineoplastic Agents
(4)
Antineoplastic Agents - Therapeutic Use
(4)
Chemotherapy
(4)
Female
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)

Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma

Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program

Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines

Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808

Phase I/II Trial of Orteronel (TAK-700)―an Investigational 17,20-Lyase Inhibitor―in Patients with Metastatic Castration-Resistant Prostate Cancer

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Predictors of response to targeted therapy in renal cell carcinoma

Segregation of two spectrin isoforms: polarized membrane-binding sites direct polarized membrane skeleton assembly

Using Intensity-Modulated Radiotherapy to Spare the Kidney in a Patient with Seminoma and a Solitary Kidney: A Case Report

Prostate cancer, version 1.2014

Chemotherapy for prostate cancer : implementing early systemic therapy to improve outcomes

Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up

Testicular cancer

Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer

Correlation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC)

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

Correlation of pathologic findings after brief neoadjuvant sorafenib (neoS) with results of dynamic-contrast enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) in patients (pts) with locally advanced or metastatic clear cell renal cell carcinoma (RCC)

Suchergebnisse filtern